Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Advance Neurological Disorder Treatments

Oragenics Inc. (NYSE American: OGEN), a biotechnology firm specializing in the development of intranasal pharmaceuticals for neurological disorders, has announced a significant financial move aimed at advancing its research and development efforts. The company has entered into a placement agency agreement for the sale of up to 800,000 shares of Series H Convertible Preferred Stock and accompanying Warrants, with each unit priced at $25.00. This strategic offering could generate gross proceeds of up to $20 million, providing essential funding for the company's ongoing and future projects.

The proceeds from this offering are earmarked for several key areas, including the support of ONP-2 concussion trials, further research and development activities, the repayment of a $3 million bridge note, and other general corporate purposes. Each Warrant included in the offering allows the purchase of an additional Preferred share at the same $25.00 price, with Preferred shares convertible into common stock at $2.50. This financial strategy underscores Oragenics' commitment to advancing its pipeline of innovative treatments for neurological disorders and infectious diseases.

Dawson James Securities, Inc. is acting as the sole placement agent for this offering, with the closing expected to occur on or about July 2, 2025. This move is a critical step for Oragenics as it seeks to solidify its position in the competitive field of biotechnology and pharmaceutical development. The company's focus on nasal delivery of pharmaceutical medications represents a promising avenue for treating conditions such as mild traumatic brain injury (mTBI), also known as concussion, and Niemann Pick Disease Type C (NPC).

For investors and stakeholders in the biotechnology sector, this announcement highlights Oragenics' proactive approach to securing the necessary capital to fuel its innovative research and development efforts. The successful completion of this offering could significantly impact the company's ability to bring new and effective treatments to market, offering hope to patients suffering from neurological disorders and infectious diseases. Further details on the offering can be found in the full press release available here.